Silo Pharma, Inc. announced that its Alzheimer?s disease therapeutic SPC-14 showed positive efficacy in small animals. Data from a study conducted at Columbia University in collaboration with Silo Pharma showed that SPC-14 was effective against LH stress in attenuating learned helplessness, perseverative behavior, and hyponeophagia (a measure of anxiety). The mice were treated twice daily with the SPC-14 therapeutic.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.68 USD | -4.55% | -9.19% | +16.67% |
23/04 | Silo Pharma, Inc. Announces Positive Results for Intranasal PTSD Treatment | CI |
10/04 | Silo Pharma Says It Exercised Option to License Alzheimer's Therapeutic From Columbia University | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+16.67% | 4.78M | |
-2.35% | 89.08B | |
+3.55% | 40.9B | |
-14.40% | 32.25B | |
+54.37% | 25.14B | |
-15.96% | 15.39B | |
-15.50% | 11.91B | |
-41.29% | 11.89B | |
-11.75% | 11.64B | |
+5.99% | 9.03B |
- Stock Market
- Equities
- SILO Stock
- News Silo Pharma, Inc.
- Silo Pharma Announces Positive Results in Alzheimer?s Disease Study